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Introduction: Neonatal encephalopathy (NE) is associated with coagulation
abnormalities. We aimed to investigate the serial alterations in coagulation profiles
in term infants with NE and correlate with their clinical outcomes. This was a prospective
cohort study in a tertiary referral, university-affiliated maternity hospital. Neonates
exposed to perinatal asphyxia were recruited (n = 82) and 39 received therapeutic
hypothermia. Infants had serial coagulation tests including platelets, prothrombin time
(PT), activated partial thromboplastin time (aPTT) and fibrinogen in the first week of life.
The main outcome measures included MRI brain and EEG seizures. Our results show
that mortality was predicted on day 1 by decreased Fibrinogen (AUC = 0.95, p = 0.009)
and by PT on day 2 with a cutoff of 22 s. An abnormal MRI was predicted by Fibrinogen
on day 3 with a cut-off value of 2 g/L. For prediction of grade II/III NE, PT on day 2 of
life was strongest with a cut-off value of 14 s. Only elevated APTT levels on day 1 of life
were predictive of seizures (AUC = 0.65, p = 0.04).
Conclusion: Coagulation parameters are strong predictors of outcomes such as
abnormal NE grade, seizures, and mortality.
Keywords: coagulopathy, neonatal encephalopathy, hypoxic-ischaemic encephalopathy, EEG, MRI
INTRODUCTION
Coagulopathy may occur as part of the spectrum of multi-organ dysfunction following a perinatal
hypoxic-ischaemic insult (1). Newborn term infants who have been exposed to an asphyxial
insult are at higher risk of disseminated intravascular coagulation (DIC) compared to normal
term newborns (2–4). Disturbances in coagulation function are common and manifest with
reduced fibrinogen levels, prolonged prothombin time (PT) and activated partial thromboplastin
time (APTT) (5, 6). Following a hypoxic, ischaemic, or septic insult a process of consumptive
coagulopathy occurs with raised levels of fibrin degradation products (FDPs), prolongation of
the PT and decreased platelet counts. A hypocoagulable state is also thought to develop with
prolongation of the APTT (7). Plasma levels of thrombin-anti-thrombin complexes, D-dimers,
fibrin degradation products, and soluble fibrin monomer complexes are also reported to be higher
in the asphyxiated term infant correlating with disseminated intravascular coagulation (2–4).
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Compared to dysfunction of other organs such as the heart or
liver, in neonatal encephalopthy (NE) there are few published
studies that have looked prospectively at the abnormalities in
coagulation and hemostasis and correlated them with outcome
or severity of NE (8). Forman et al. found that infants with NE (n
= 76) had bleeding events in 54% of cases but that all infants had
coagulopathy (9). Therapeutic hypothermia in both children and
adults is associated with coagulopathy although not sufficiently
severe to require discontinuation of TH (10).
We hypothesized that there is an association between
term babies with neonatal encephalopathy who are at risk of
coagulation abnormalities, and severity of NE and outcome. We
aimed to confirm that coagulation abnormalities observed in
neonates with NE, may be used in the prediction of adverse
neonatal outcomes, represented by the severity of neonatal
encephalopathy, neonatal mortality, seizures development, as
well as altered MRI.
METHODS
The study was approved by the Ethics Committee of the National
Maternity Hospital, Dublin, a tertiary referral, University-
affiliated Maternity hospital with ∼9,500 deliveries per annum
for the study period and is one of four national referral
centers for Therapeutic Hypothermia. In all cases, written
informed consent was taken from parents of infants enrolled
in the study for the research period of February 2011–
December 2012. The following infants were enrolled: neonates
exposed to perinatal asphyxia (PA) as previously described (11).
Infants with congenital abnormalities or evidence of maternal
substance abuse were excluded. On completion of the study,
infants exposed to PA were divided into subgroups according
to the classification of Sarnat and Sarnat (12): (a) NE 0/I:
infants who required resuscitation following delivery with no
neurological signs or mild encephalopathy; (b) NE II/ III:
moderate/severe encephalopathy.
Coagulation Screens
Serial coagulation samples were taken as part of routine care.
Arterial samples were taken when peripheral or umbilical arterial
catheters were in situ, otherwise peripheral venous samples
were obtained including precautions to prevent heparin sample
contamination (13). Coagulation screens were analyzed using the
Sysmex CS-2100i coagulation analyser and full blood counts as
part of validated laboratory practices.
Data and Statistical Analysis
Coagulation results were available from 79 of the 82 infants
enrolled in the study. If more than one coagulation screen was
taken each day, the maximum value for PT, APTT, and INR
was recorded for each time point while the minimum value for
fibrinogen and platelets was recorded for each time point. In
Abbreviations: NE, Neonatal encephalopathy; PT, Prothrombin time; aPTT,
Activated partial thromboplastin time; INR, International normalized ratio;
DIC, Disseminated intravascular coagulation; PA, Perinatal asphyxia; TH,
Therapeutic Hypothermia; ROC, Receiver operating characteristic; TOBY, Total
Body Hypothermia for Neonatal Encephalopathy.
general the data showed a skewed distribution and therefore
medians, interquartile ranges, minimums, and maximums were
calculated (Figure 1). Non-parametric tests i.e., the Mann–
Whitney U-test was utilized to compare each coagulation
parameter at each time point with the treatment Therapeutic
Hypothermia and outcomes such as seizure occurrence, grouping
of grade of NE, MRI brain result, and mortality.
Maximum PT, APTT, and minimum fibrinogen levels
were compared to therapeutic hypothermia and outcomes as
previously listed using the Mann–Whitney U-test (Table 2). For
certain comparisons i.e., those with a number of<5 observations
in one of the groups, it was necessary to run a Kruskal–Wallis
test with Monte Carlo significance to analyse this data more
closely. Receiver Operating Characteristic Curve analysis was
employed to assess the coagulation parameters for ability to
predict outcome. Using the student-t-test, the means of all the
coagulation variables were compared to TH and to outcome
measures: occurrence of seizures, grouping of grade of NE and
MRI brain result.
Statistical analysis was carried out using the PASW statistical
package version 18 (www.ibm.com/SPSS_Statistics). Normally
distributed data were expressed using means ± standard
deviations (SD) and the Student t-test, while skewed data
were expressed using medians and IQRs and the Mann–
initially assumed for values of p < 0.05 with 95% confidence
interval (CI). A Bonferroni correction for multiple testing was
employed by altering the threshold for “significance.” This was
achieved by dividing the threshold for “significance” that is
0.05 by the number of tests carried out. We left in situ the
original p-values but annotated the p-values which still retained
significance at a Bonferroni corrected level. Receiver operating
characteristic (ROC) curve analysis was employed amongst the
PA infants looking at the outcome of NE grade and cut-off values
were calculated.
RESULTS
The study included infants exposed to PA (n = 82) and the
mean values (SD) were as follows within NE 0/I vs. NE II/III:
gestation: 39.9 ± 1.6 vs. 40.6 ± 1.6 weeks; birth weight: 3.5 ±
0.7 vs. 3.7 ± 0.7 kg and male gender: 69 vs. 64%. Thirty-nine
infants required TH in accordance with the TOBY (Total Body
Hypothermia for Neonatal Encephalopathy) criteria (13) and
were treated for 72 h duration. Clinical seizures developed in 39
infants and 4 infants died. The NE group II/III were significantly
more likely to have the following features: outborn, lower 1, 5,
and 10min Apgar scores, clinical seizures, TH, abnormal MRI
brain imaging, and significantly lower admission pH, admission
bicarbonate, higher ALT, AST, and CK levels and larger base
excess values compared to NE group 0/I. However, there were
no significant differences between the NE groups 0/I and II/III
with regard to gestational age, birth weight, gender, mode of
delivery, multiplicity, mortality, cord pH, cord base excess, and
cord lactate values as previously described (11).
MRI brain scans were performed on 66 infants (normal
n = 35) and scored and reported independently by a
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FIGURE 1 | Serial daily coagulation values in neonatal encephalopathy analyzed on day 1–day 7 including (A) Prothrombin time, (B) INR, (C) APPT, and
(D) Fibrinogen.
pediatric radiologist according to the Barkovich criteria divided
into “normal” (score = 0) and “abnormal” (score = 1–4)
neuroimaging groups for the purpose of data analysis (11).
Barkovich scores were available for the MRI brain scans of 63
infants with NE giving the following results: Basal Ganglia (BG)
score: 1 (n = 3); 2 (n = 2); 3 (n = 2); 4 (n = 6). Watershed (W)
score=1 (n = 7); 2 (n = 3); 4 (n = 3); 5 (n = 3). Combined
Basal Ganglia/Watershed (BG/W) score= 1 (n= 5); 2 (n= 10); 3
(n= 6); 4 (n= 1).
Coagulation Results
Eighty-two infants were recruited to the study and five infants
showed evidence of frank bleeding in at least one of the
following categories: pulmonary hemorrhage (n = 3); frank
hematuria (n = 3); significant umbilical bleeding (n = 2);
nasal bleed (n = 1); fresh blood in gastric aspirates (n =
3). Four infants demonstrated evidence of minor bleeding:
leakage of umbilical serosanguinous fluid (n = 3); post capillary
blood sampling bleeding (n = 1). Excluding the finding of a
cephalohaematoma, only one infant had significant superficial
bruising. Another infant was later diagnosed aged 16 months
with a mild thrombophilia disorder (Factor V Leiden deficiency).
Platelet levels were significantly lower in infants with frank
bleeding compared to the remaining infants (mean ± SD: 79 ±
45 × 109/L vs. 170 ± 70 × 109/L; p = 0.001). In the infants
with frank bleeding (pulmonary, hematuria, umbilical, nasal,
or gastric) the coagulation results were as follows: the average
maximum PT was 52 s, Max aPTT was 94 s and Minimum
Fibrinogen 0.64 s.
TABLE 1 | Blood products requirements in infants with NE.
Blood product No. of infants* No. of blood productspi
Red cell transfusion 10 18
Platelets 8 12
Octaplas 10 16
Fresh frozen plasma 2 2
Fibrinogen 9 12
Vitamin K 16 28
Albumin 20% 5 6
Total 60 94
*Number of Infants receiving at least one dose of each blood product.
piTotal numbers of each type of blood product received by study infants.
Twenty-six infants required at least one blood product during
their NICU admission (Table 1). In total there were 94 blood
products administered to the infants with NE over the study
period including additional vitamin K. Vitamin K was the most
commonly administered medication for correction of prolonged
PT (n = 28) with red cell transfusion being the most common
form of blood product given (n = 18 transfusions). Human
Pooled Plasma, Solvent/Detergent Treated (Octaplas n= 16) was
much more commonly administered than Fresh Frozen Plasma
(FFP n= 2).
The Chi-squared test was used to compare the categorical
variables of TH, presence of seizures, grade of encephalopathy
by group, MRI brain result and the hematological categorical
variables of frank bleeding, pulmonary hemorrhage, minor
bleeding, bruising/petechiae, thrombophilia, and requirement
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for blood products. There was a significant association between
grouping of grade of NE i.e., normal (Sarnat grade 0 and I) and
abnormal (Sarnat grade II and III) and requirement for blood
products [χ2
(1)
10.88, p = 0.001, OR 7.45]. An infant with NE
II/III was 7.45 times more likely to require blood products. There
was a significant association between TH and requirement for
blood products [χ2
(1)
= 11.16, p = 0.001, OR = 5.31]. If an
infant required TH, they were 5.31 times more likely to require
blood products than if they were not cooled. The occurrence
of seizures was not associated with any of the hematological
variables measured, including requirement for blood products.
There was no significant association between MRI result or
neurological examination at discharge and any of the clinical
hematological variables measured (Table 2).
PT, INR, and APTT levels on day 1–3 were significantly
elevated in infants undergoing TH (p ≤ 0.001). While fibrinogen
levels were significantly decreased in infants who received TH
only on day 1 and 2 of life (p = 0.001, 0.007, respectively). The
APTT level on day 1 of life was the only coagulation parameter
significantly associated with seizure occurrence (p = 0.04). PT,
INR, and APTT levels on day 1, 2, and 3 were significantly
elevated in infants with grade II/III NE (all p< 0.002).While only
fibrinogen levels on day 1 were significantly decreased in infants
with grade II/III NE (p = 0.04). PT and INR levels on day 7 of
life were significantly elevated in infants with an abnormal MRI
result (p= 0.03) and fibrinogen levels on day 3 were significantly
decreased (p = 0.02). Infants who died had significantly higher
PT, INR, and APTT levels on day 1 (p = 0.007, 0.006, 0.007) and
day 2 (p = 0.006, 0.008, and 0.04), respectively. However, death
was significantly associated with lower fibrinogen levels only on
day 1 of life (p= 0.009) (Figure 1).
Maximum PT values for each patient were significantly
elevated in infants who underwent TH, had grade II/III NE
or died (p < 0.001, p < 0.001, p = 0.002, respectively).
Maximum APTT values were significantly elevated in infants
who underwent TH, had seizures, NE II/III, and those who died
(p < 0.001, p = 0.048, p < 0.001, and p = 0.003, respectively).
Minimum fibrinogen values for each patient were significantly
lower in those infants who underwent TH, had grade II/III
NE and those who did not survive (p < 0.001, p = 0.03,
and p = 0.002, respectively) (Table 3). Grade II/III NE was
significantly associated with lower mean (SD) platelet count
on day 2, 3, and 6 [157.5(65.5) vs. 220.1(54.7); 154.9(75.2) vs.
235.3(73.3); 136.4(85.1) vs. 299.5(62.9) × 109/L, respectively].
Platelet counts were significantly negatively associated with
abnormal NE II/III on day 1, 2, 3, and 6 (p = 0.02, 0.001, 0.006,
and 0.02, respectively). There were no significant associations
found between maximum PT, APTT, and minimum fibrinogen
and infants with an abnormal MRI brain result (Table 3).
Day 3 values for PT, APTT and fibrinogen when compared to
NE grade fitted this criteria. Using Kruskal-Wallis, the significant
association between elevated PT, APTT, and grade II/III NE
remained (mean rank 21.43 vs. 3.13, Monte Carlo p <0.001 and
mean rank 20.91 vs. 3.25, Monte Carlo p < 0.001, respectively).
With regard to the outcome of mortality there were small
numbers in one of the groups for PT, APTT, and fibrinogen values
across day 1–3. Further analysis of these comparisons using the
Kruskal–Wallis test and Monte Carlo significance revealed that
the significant associations between higher PT and APTT values
on day 1 and 2 and lower fibrinogen values on day 1 in those
infants who died, remained true. Similarly for maximum PT,
APTT, and minimum fibrinogen values for each patient there
remained a significant association between higher maximum
PT, APTT values, and lower minimum fibrinogen values with
mortality (Table 4).
In order to look more closely at the relationship between
coagulation values and grade of encephalopathy (normal= 0 was
excluded from analysis, mild = I, moderate = II, severe = III),
PT and APTT levels on day 1, 2, 3 and fibrinogen levels on day
1 only, were significantly associated with grade of NE (Figure 2).
TABLE 2 | Relationship between hematological and short-term outcome variables in NE.
Hematological
variables
TH Seizures NE group MRI
() χ2 p (pi) () χ2 p (pi) () χ2 p (pi) () χ2 p (pi)
Frank bleeding (1)
6.27
0.01* (1)
0.43
0.51* (1)
3.21
0.07* (1)
0.56
0.45*
Pulm haem (1)
3.67
0.06* (1)
3.67
0.06* (1)
1.88
0.17* (1)
2.46
0.12*
Minor bleeding (1)
4.95
0.03* (1)
4.95
0.03* (1)
2.53
0.11* (1)
1.48
0.22*
Bruise/petechia (1)
1.19
0.28* (1)
1.19
0.28* (1)
0.61
0.43* (1)
0.85
0.36*
Thrombophilia (1)
0.86
0.35* (1)
1.19
0.28* (1)
0.61
0.43* (1)
1.21
0.27*
Blood product
requirement
(1)
11.16
0.001
(5.31)
(1)
2.1
0.15 (1)
10.88
0.001
(7.45)
(1)
1.05
0.31
χ, Chi-squared test employed for comparisons; χ2, Chi-squared test statistic (degrees of freedom =); p, p < 0.05 taken as significant; *Expected count less than 5, therefore the
chi-square test accuracy unreliable; pi, Odds ratio if significant; Pulm Haem, Pulmonary Hemorrhage; TH, Therapeutic Hypothermia.
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TABLE 3 | Associations between TH, outcome measures and coagulation parameters of infants with NE.
Haem variable TH NE Grade Death
D Median p Median p Median p
PT 1 17.5 (16.1–22.7),
13.9 (13–17.1)
<0.001 17.8 (16–22.7),
13.9 (13.2–16.6)
<0.001 53.9 (22.9–53.9)*,
16.7 (14–19.3)
0.007
2 15.8 (14.3–20.3),
12.5 (11.4–13.4)
<0.001 15.3 (13.9–19.6),
12.5 (11.5–13.4)
<0.001 32.8 (22.6–32.8)*,
14.4 (12.5–16.1)
0.006
3 16.1 (13.6–17.9),
10.9 (10.5–13.5)
<0.001 14.7 (13.4–17.6),
10.6 (10.1–10.9)
0.002 21.7 (15.9–21.7)*,
13.9 (12.4–17.4)
0.15
7 N/A N/A 11.5 (10.9–13.3),
11.4*
0.71 N/A N/A
APTT 1 40.3 (34.8–46.6),
31.3 (27.3–35.6)
<0.001 39.4 (33.2–45.2),
31.4 (28.7–35.6)
<0.001 71.1 (45.6–71.1)*,
35.8 (31.2–40.7)
0.008
2 37.8 (35.2–45.3),
30.9 (27.8–33.9)
<0.001 36 (33.2–42.6),
31 (28–34)
0.002 42.8 (41.9–42.8)*,
34.5 (31.1–38.1)
0.04
3 41.7 (38–48.6),
29.1 (26.2–33.5)
<0.001 39.1 (34.4–45.8),
26.2 (25.1–28)
0.002 45.9 (43.9–45.9)*,
38 (32.2–44.3)
0.18
7 N/A N/A 30.1 (28.3–32),
31.5*
0.39 N/A N/A
Fib 1 1.3 (1–1.7),
1.8 (1.4–2.1)
0.001 1.3 (1–2),
1.7 (1.4–2.1)
0.04 0.61 (0.27–0.61)*,
1.5 (1.2–2)
0.009
2 2.1 (1.7–2.4),
2.5 (2.2–3.1)
0.007 2.1 (1.7–2.6),
2.5 (2.1–3.1)
0.05 1.9 (0.4–1.9)*,
2.2 (1.8–2.7)
0.07
3 2.1 (2–3),
2.6 (1.8–3.2)
0.59 2.2 (1.9–3),
2.8 (2.4–3.6)
0.15 2.0 (2–2)*,
2.4 (2.0–3.1)
0.23
7 N/A N/A 2.6 (2–3.3),
2.8*
0.71 N/A N/A
Medians (IQR) of cooled vs. non-cooled infants, abnormal vs. normal NE grade and death vs. survival, followed by a p-value (p); D, Day; PT, Prothrombin Time (secs); APTT, Activated
Partial Thromboplastin Time (secs); Fib, Fibrinogen (g/L); N/S, Not significant; N/A, Not applicable due to missing values; *No IQR available due to small numbers.
TABLE 4 | Comparison of maximum PT, APTT, and minimum fibrinogen values for each infant with outcomes.
Coag value TH Seizures NE grade Death
Rank p rank p Rank p Rank p
Max
PT
54.37,
25.99
<0.001 43.33,
36.75
0.20 25.37,
47.18
<0.001 74.0,
38.19
0.002
Max APTT 56.83,
23.59
<0.001 45.18,
34.95
0.048 22.96,
48.36
<0.001 73.25,
38.23
0.003
Min fib 27.44,
52.25
<0.001 39.73,
40.26
0.92 48.25,
35.95
0.03 5.5,
41.84
0.002
However, it was not possible to examine this relationship further
using an ANOVA as the variance of the data was too different and
the data was not normally distributed. Elevated PT and APTT on
day 1, 2, and 3 were predictive of TH (p< 0.001), while decreased
fibrinogen levels on day 1 and 2 were predictive of TH (AUC =
0.75, 0.72, p = 0.001, 0.007, respectively). Only elevated APTT
levels on day 1 of life were predictive of seizure occurrence (AUC
= 0.65, p= 0.04). Increased PT and APTT levels on day 1, 2, and
3 of life were predictive of grade II/III NE with excellent AUCs
of ≥0.80 (all p < 0.002). Low fibrinogen levels on day 1 of life
were predictive of abnormal grade II/III NE (AUC = 0.66, p =
0.04). Only a raised PT level on day 7 of life along with decreased
fibrinogen level on 3 of life were predictive of an abnormal MRI
brain scan (AUC = 0.88, p = 0.03, AUC = 0.73, p = 0.02).
Mortality was strongly predicted by raised PT levels on day 1 and
2 of life (AUC= 0.96, p= 0.008, AUC= 0.98, p = 0.006) and by
raised APTT levels on day 1 and 2 of life also (AUC = 0.95, p =
0.008, AUC = 0.85, p = 0.04). While only decreased fibrinogen
levels on day 1 of life were strongly predictive of mortality (AUC
= 0.95, p= 0.009).
APTT on day 1 of life was the best predictor of seizure
occurrence with a cut-off value of 37 s. Fibrinogen on day 3 of
life was the best predictor of an abnormal MRI brain scan result
with a cut-off value of 2 g/L. Finally for prediction of death, PT
on day 2 of life was the best predictor with a cut off value of 22 s
to predict mortality.
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FIGURE 2 | Coagulation screens and correlation with clincial outcomes. (A) APTT, Activated Partial Thromboplastin Time (s); (B) PT, Prothrombin Time (s); (C) Fib,
Fibrinogen (g/L). Grade I NE, Mild; Grade II NE, Moderate; Grade III NE, Severe.
DISCUSSION
PT and APTT levels are increased while fibrinogen and platelet
levels were significantly decreased in infants who required
TH, had grade II/III NE and in non-survivors. Coagulation
parameters were strong predictors of outcomes such as abnormal
NE grade and death. Cut-off values of PT, APTT, and fibrinogen
for predicting such outcomes may in the future be incorporated
into a biomarker panel for outcome prediction.
The prothrombin time measures factors I, II, V, VII, X
which are all manufactured in the liver and therefore the PT
is also a useful test of liver function, since there is a good
correlation between abnormalities in coagulation measured by
the prothrombin time and the degree of liver dysfunction. The PT
measures the extrinsic pathway of coagulation, however in adults,
the PT is compared to a normal control sample and given as a
ratio called the international normalized ratio (INR) which allows
that all results are standardized irrespective of which analytical
system is used to measure the PT. In newborns, the actual PT is
quoted and the INR is less commonly used (6).
The INR of a group of 26 asphyxiated infants rose significantly
on day 1 and 2 of life compared to normal control infants,
however was shown to normalize by day 3. Furthermore,
Beshlawy et al. showed a marked decrease in the level of the
physiological inhibition system of coagulation with significant
decreases in mean levels of antithrombin III (38.4 vs. 78.5%),
protein C (10.46 vs. 32.63%), and protein S (18.66 vs. 48.66%) in
all 10 neonates with NE compared to control infants before the
occurrence of thromboembolic complications (5). The following
occurred: DIC and died (n = 5); necrotizing enterocolitis and
rectal bleeding (n = 4); hematuria (n = 2); hematemesis (n
= 3); intracranial hemorrhage (n = 2); seizures (n = 10)
and all 10 neonates with NE had prolongation of the PT and
APTT. The study concluded that based on the development
of antithrombin III and protein C concentrates, which are
commercially available, require minimal monitoring, and have
very few side effects, there is a strong argument for the
prompt evaluation of the optimal treatment for thromboembolic
accidents in NE. Pakvasa et al. demonstrated that 69% of infants
has hemostatic dysfunction. From a cohort of 98 infants with
NE, they noted that 57% required at least one blood product
which was predominantly fresh frozen plasma (14). There is
controversy regarding transfusion thresholds in neonates and a
more conservative approach has been suggested which is more
in keeping with the transfusion policy in our study (15, 16). The
limitations in this study include the sample size and that timing
of sampling was linked with clinical indication and so varied in
the first day of life.
Infants with NE have multiorgan dysfunction and
coagulopathy is common. In the first few days of life coagulation
is measured routinely and this study demonstrates the utility of
these routine markers in predicting outcome. Further research to
determine cutoff values for interventions such as blood product
administration are required.
WHAT IS KNOWN
Coagulopathy is associated with hypoxia-ischaemia and is
described in Neonatal Encephalopathy.
WHAT IS NEW
Coagulation markers are associated with seizures, MRI and
mortality in Neonatal Encephalopathy.
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